Rosuvastatin Effect on Telomere-telomerase System in ACS

• Status: Unknown status
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Coronary heart disease (CHD) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. The mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. Telomere length and telomerase activity, therefore, correlates with the risk of CHD and atherosclerosis. A present study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. This suggests a positive relationship of telomere and telomerase system with the treatment with statins in CHD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiao-dong Zhuang
• Collaborator: Sun Yat-sen University
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Subjects with ACS, planing for PCI treatment

• Male or females who are 18-80years of age

• No current or previous statin therapy

• No current indication for statin therapy (Coronary artery disease; hypercholesterolemia, renal dysfunction)

• Subjects who have given their signed consent to participate in the study

Exclusion Criteria:

• Patient < 18 or > 80 years

• Renal dysfunction

• Hyperlipidemia

• Active myositis

• All forms of liver disease

• Pregnancy

• Breastfeeding

• Patients being treated with other type statin